A Randomized Phase I/II Study to Assess the Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-Level Deep Venous Thrombosis
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs GMI 1271 (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis
- Focus Adverse reactions
- Sponsors GlycoMimetics
- 24 Apr 2017 Status changed from recruiting to completed.
- 08 Jul 2016 Status changed from not yet recruiting to recruiting.
- 22 Apr 2016 New trial record